lunes, 28 de julio de 2014

Clinical Pharmacology & Therapeutics - Abstract of article: Individualizing the Use of Medications in Children: Making Goldilocks Happy

Clinical Pharmacology & Therapeutics - Abstract of article: Individualizing the Use of Medications in Children: Making Goldilocks Happy



Clinical Pharmacology & Therapeutics advance online publication 23 July 2014; doi: 10.1038/clpt.2014.130

Individualizing the Use of Medications in Children: Making Goldilocks Happy

J S Leeder1, J T Brown1 and S E Soden2
  1. 1Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children’s Mercy Hospitals and Clinics, University of Missouri–Kansas City, Kansas City, Missouri, USA
  2. 2Division of Developmental and Behavioral Sciences, Department of Pediatrics, Children’s Mercy Hospitals and Clinics, University of Missouri–Kansas City, Kansas City, Missouri, USA
Correspondence: J S Leeder, (sleeder@cmh.edu)
Received 16 May 2014; Accepted 9 June 2014
Accepted article preview online 13 June 2014; Advance online publication 23 July 2014
Top

Abstract

To date, implementation of precision medicine for children has been limited. Extrapolation of adult experience streamlines pediatric drug development programs, and physiologically based pharmacokinetic models aid pediatric dose selection on a population basis. To achieve clinically viable individualization of drug therapy, genotype-stratified pharmacokinetic studies can efficiently characterize the extremes of the dose–exposure relationship. Reducing variability in exposure through genotype-based dosing may improve identification of genetic factors contributing to response, ultimately improving drug therapy for children.

No hay comentarios:

Publicar un comentario